摘要
原发性肝癌是我国第3位致死性肿瘤,其中85%以上是肝细胞癌(HCC)。肝癌进展快、易转移,这为治疗带来较大困难。近年来,以嵌合抗原受体T细胞免疫治疗为代表的细胞免疫治疗及菌群治疗在中晚期HCC的治疗中受到越来越广泛的关注。文章将总结肝癌的细胞免疫治疗及肠道益生菌治疗现状,旨在为临床治疗原发性肝癌提供新的思路。
Primary liver cancer is the third fatal tumor in China, and 85% of them are Hepatocellular Carcinoma (HCC). Liver cancer progresses quickly and is easy to metastasize, which brings great difficulties for treatment. In recent years, great breakthroughs have been made in the treatment of advanced HCC by chimeric antigen receptor T cell (CAR-T) immunotherapy and flora treatment. This article reviewed the current status of cellular immunotherapy and intestinal probiotics therapy for HCC, aiming at providing new ideas for clinical treatment of liver carcinoma.
作者
季国忠
王静静
JI Guo-zhong;WANG Jing-jing(Digestive Department,the Second Affiliated Hospital of Nanjing Medical University,Nanjing 210011,Jiangsu,China)
出处
《医学研究生学报》
CAS
北大核心
2019年第7期673-677,共5页
Journal of Medical Postgraduates
基金
江苏省重点研发计划项目(BE2016799)
关键词
原发性肝癌
肝细胞癌
细胞免疫治疗
肠道益生菌治疗
primary liver cancer
hepatocellular carcinoma
cellular immunotherapy
intestinal probiotics therapy
